glp-1 for ckd Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease Contrary to popular belief: GLP-1
Description
The mean age was nearly identical (59.3 vs
Evidence calibration: current studies on improving ART outcomes are primarily small-scale and heterogeneous, suggesting possible benefit rather than a definitive guarantee (154, 193196)
DOI: 10.3390/nu13072228, Jochum, C
Importance of Patient Education and Support Patient education is crucial in managing side effects and ensuring successful treatment with semaglutide
April 23, 2024
